文献速递中枢神经肿瘤放疗姑息放疗与转移瘤放疗物理与技术

可切除脑转移瘤患者术前与术后单次及分次立体定向放疗的比较

Comparing pre-operative versus post-operative single and multi-fraction stereotactic radiotherapy for patients with resectable brain metastases.
PubMed 文献 · Clin Transl Radiat Oncol · 2022-11-09

多机构分析纳入279例接受手术切除及立体定向放疗的脑转移瘤患者,中位随访9个月,87%接受分次治疗,29%接受术前治疗。术后SRS、术后FSRT、术前SRS和术前FSRT的复合终点发生率分别为0%、17%、15%和7.5%。作者认为术前FSRT的复合终点7.5%优于术后FSRT的17%,术前FSRT观察到较低的局部失败、脑膜疾病和放射性坏死发生率,需要前瞻性验证。

要点

  • 279例可切除脑转移瘤患者中,术前FSRT的复合终点发生率为7.5%,低于术后FSRT的17%。
  • 术后SRS、术后FSRT、术前SRS和术前FSRT的复合终点发生率分别为0%、17%、15%和7.5%。
  • 作者结论指出术前FSRT的局部失败、脑膜疾病和放射性坏死发生率低,但需要前瞻性验证。

核心结论

  • 作者认为术前FSRT的复合终点7.5%优于术后FSRT的17%,术前FSRT观察到较低的局部失败、脑膜疾病和放射性坏死发生率,需要前瞻性验证。

研究设计与样本

  • 多机构分析,纳入279例接受手术切除及立体定向放疗以治疗至少一个脑转移瘤的患者,中位随访9个月。

主要发现

  • 术后SRS(n=10)、术后FSRT(n=189)、术前SRS(n=27)和术前FSRT(n=53)的复合终点发生率分别为0%、17%、15%和7.5%。
  • 87%的患者接受分次治疗,29%的患者接受术前治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The standard treatment for patients with large brain metastases and limited intracranial disease is surgical resection and post-operative stereotactic radiosurgery (SRS). However, post-operative SRS still has elevated rates of local failure (LF) and is complicated by radiation necrosis (RN), and meningeal disease (MD). Pre-operative SRS may reduce the risk of RN and MD, while fractionated therapy may improve local control through delivering a higher biological effective dose. We hypothesize that pre-operative fractionated stereotactic radiation therapy (FSRT) will have less toxicity compared to patients who receive post-operative SRS or FSRT. METHODS: A multi-institutional analysis was conducted and included patients who had surgical resection and stereotactic radiation therapy to treat at least one brain metastasis. Pertinent demographic, clinical, radiation, surgical, and follow up data were collected for each patient. The primary outcome was a composite endpoint defined as patients with one of the following adverse events: 1) LF, 2) MD, and/or 3) Grade 2 or higher (symptomatic) RN. RESULTS: 279 patients were eligible for analysis. The median follow-up time was 9 months. 87 % of patients received fractionated treatment. 29 % of patients received pre-operative treatment. The composite endpoint incidences for post-operative SRS (n = 10), post-operative FSRT (n = 189), pre-operative SRS (n = 27), and pre-operative FSRT (n = 53) were 0 %, 17 %, 15 %, and 7.5 %, respectively. CONCLUSIONS: In our study, the composite endpoint of 7.5% for pre-operative FSRT compares favorably to our post-operative FSRT rate of 17%. Pre-operative FSRT was observed to have low rates of LF, MD, and RN. Prospective validation is needed.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Perlow HK, Ho C, Matsui JK, et al. Comparing pre-operative versus post-operative single and multi-fraction stereotactic radiotherapy for patients with resectable brain metastases. Clin Transl Radiat Oncol. 2022. PMID: 36420099. doi:10.1016/j.ctro.2022.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。